SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement a 1-for-4 reverse split of its common stock. The reverse stock split will be effective as of the morning of January 28, 2026, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol "REVB. ...

Core Viewpoint - Revelation Biosciences, Inc. has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 13,065,000 shares of common stock at a reduced exercise price of $0.86 per share [1]. Group 1 - The company is a clinical-stage life sciences firm focused on rebalancing inflammation [1]. - The existing warrants were issued on September 11, 2025 [1]. - The shares of common stock that can be issued upon exercise of the existing warrants are registered under an effective registration statement on Form S-3 [1].

- Single Phase 2/3 Adaptive Study Design - - Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, announced that the Company has reached agreement with the FDA on an approval pathway for Gemini as a treatment for Acute Kidney Injury (AKI). The two key agreements were 1) a clinically relevant and obj ...

- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ACCESS Newswire / January 14, 2026 / Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, announced today that new clinical data on the potential therapeutic benefit of Gemini for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the Interna ...

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP manufacturing of GEMINI and placebo. This manufacturing run will provide the Company with clinical drug supply for later stage clinical studies. "We are delighted to be working with a leading global contract manufacturing organization," said James Rolke, Chief Execut ...

Core Viewpoint - Revelation Biosciences, Inc. has successfully reached a quorum for its Special Meeting scheduled for December 3, 2025, indicating strong shareholder engagement [1] Company Summary - The company is a clinical-stage life sciences firm focused on rebalancing inflammation [1] - Shareholders are reminded that voting is open until 11:59pm ET on December 2, 2025 [1]

Core Insights - Revelation Biosciences, Inc. has successfully submitted and received acceptance for the end-of-phase 1 meeting package to the FDA [1] - The company is on track to hold the meeting later this year, which aims to gather agency feedback on the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI) [1] Company Developments - The primary focus of the meeting with the FDA is to establish feedback regarding the clinical development of Gemini [1] - The company is positioned as a clinical-stage life sciences entity concentrating on rebalancing inflammation [1]

Financial Position - As of September 30, 2025, Revelation had $12.7 million in cash and cash equivalents, up from $6.5 million as of December 31, 2024, primarily due to net cash proceeds from a public offering and warrant inducement[2]. - The total assets of Revelation as of September 30, 2025, were $12.86 million, compared to $6.62 million as of December 31, 2024[12]. - Revelation's accumulated deficit as of September 30, 2025, was $(46.91) million, up from $(40.51) million as of December 31, 2024[12]. Operating Performance - Net cash used for operating activities for the nine months ended September 30, 2025, was $6.3 million, a significant decrease from $14.6 million for the same period in 2024[2]. - Revelation's net loss for the three months ended September 30, 2025, was $1.9 million, or $(1.77) per share, compared to a net loss of $2.2 million, or $(40.15) per share for the same period in 2024[2][10]. - For the nine months ended September 30, 2025, the net loss was $6.4 million, or $(9.76) per share, compared to a net loss of $13.3 million, or $(354.05) per share for the same period in 2024[2][10]. - Total operating expenses for the three months ended September 30, 2025, were $1.94 million, compared to $1.80 million for the same period in 2024[10]. Development Focus - The company is focused on the development of Gemini, which aims to treat acute kidney injury, chronic kidney disease, and other inflammatory conditions[4][7]. - Revelation plans to meet with the FDA later this year to discuss the clinical development path for Gemini[2]. Fundraising Activities - Revelation received gross proceeds of $9.6 million from warrant inducement in September 2025[5].

Core Insights - Revelation Biosciences, Inc. reported financial results for the three and nine months ended September 30, 2025, highlighting significant corporate developments [1] Financial Performance - The company received gross proceeds of $9.6 million from warrant inducement in September 2025, indicating strong financial backing [1] Clinical Developments - Revelation announced groundbreaking top-line results from the PRIME Clinical Study, which are expected to advance the company's development phase [1] Leadership Commentary - CEO James Rolke emphasized that the outstanding PRIME data and subsequent financing validate the potential of Gemini, positioning the company on solid footing for future advancements [1]

Financial Performance - The company incurred a net loss of $6.4 million for the nine months ended September 30, 2025, compared to a net loss of $13.3 million for the same period in 2024[99]. - The company has incurred recurring losses since inception, with net losses expected to fluctuate significantly based on clinical study timing and expenditures[99]. - The company incurred a net loss of $6.4 million for the nine months ended September 30, 2025, with an accumulated deficit of $46.9 million[122]. - Significant operating and net losses are expected to continue as the company expands research and development activities[122]. Cash Position - As of September 30, 2025, the company had cash and cash equivalents of $12.7 million and an accumulated deficit of $46.9 million[118]. - Cash and cash equivalents available as of September 30, 2025, were $12.7 million, which is insufficient to sustain operations for one year[122]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $6.3 million, a decrease from $14.6 million in the same period of 2024[125][127]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $12.5 million, primarily from a public offering and warrant inducement[129]. - There were no net cash provided by or used in investing activities during the nine months ended September 30, 2025[128]. Expenses - Research and development expenses increased by $0.2 million, from $2.9 million for the nine months ended September 30, 2024, to $3.1 million for the same period in 2025[112]. - General and administrative expenses increased by $0.1 million, from $3.3 million for the nine months ended September 30, 2024, to $3.4 million for the same period in 2025[114]. - Total operating expenses for the nine months ended September 30, 2025, were $6.5 million, compared to $6.2 million for the same period in 2024[110]. - The company expects research and development expenses to increase substantially as it continues the development of product candidates[106]. Revenue Generation - The company has never generated revenue and does not expect to do so until product candidates successfully complete development and obtain regulatory approval[101]. - The company has never generated revenue and does not expect to do so until product candidates receive regulatory approval, which may take several years[122]. Funding and Capital - The company plans to seek additional funding through public or private equity or debt financings[98]. - The company plans to seek additional funding through public or private equity or debt financings to continue operations[123]. - The company may face dilution of existing stockholders' interests if additional capital is raised through equity offerings[121]. Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements as of September 30, 2025[132].